Table 2.
Fetal AA sensitivity to U46619, ACh, and SNP
| Maternal Treatment | Agonist | Effective concentration | WT Male | WT Female | P0 Male | P0 Female |
|---|---|---|---|---|---|---|
| Control | U46619 | EC20 | 4.5 ± 0.9 (11) | 2.7 ± 0.5 (11) | 4.5 ± 0.9 (10) | 4.7 ± 1.3 (11) |
| EC50 | 18.9 ± 3.6 (11) | 10.8 ± 1.9 (11) | 17.9 ± 3.6 (10) | 18.9 ± 5.0 (11) | ||
| EC80 | 49.0 ± 10.7 (11) | 43.4 ± 7.7 (11) | 71.7 ± 14.6 (10) | 75.6 ± 19.9 (11) | ||
| ACH | EC20 | 75.2 ± 39.1 (11)A | 56.1 ± 21.8 (11) | 42.2 ± 13.7 (6) | 28.7 ± 12.0 (11)B | |
| EC50 | 300 ± 156 (11)A | 224 ± 87.3 (11) | 169 ± 54.8 (6) | 115 ± 48.0 (11)B | ||
| EC80 | 515 ± 101 (11) | 844 ± 300 (11) | 858 ± 253 (6) | 397 ± 155 (11)C | ||
| SNP | EC20 | 60.1 ± 8.6 (11) | 60.2 ± 10.7 (11) | 104 ± 31.5 (9) | 40.1 ± 4.8 (11)D | |
| EC50 | 240 ± 34.5 (11) | 241 ± 42.6 (11) | 417 ± 126 (9) | 161 ± 19.3 (11)D | ||
| EC80 | 1030 ± 193 (11) | 1045 ± 189 (11) | 1612 ± 481 (9) | 637 ± 118 (11)E | ||
| Viagra | U46619 | EC20 | 8.00 ± 1.0 (10) | 8.4 ± 2.6 (6) | 8.3 ± 1.4 (7) | 7.35 ± 1.5 (8) |
| (SC) | EC50 | 32.0 ± 3.9 (10) | 33.7 ± 10.2 (6) | 33.2 ± 5.5 (7) | 29.4 ± 5.8 (8) | |
| EC80 | 128 ± 15.5 (10) | 135 ± 41.0 (6) | 133 ± 21.9 (7) | 118 ± 23.2 (8) | ||
| ACH | EC20 | 248 ± 96.8 (8)A | 106 ± 25.2 (6) | 67.1 ± 16.7 (6) | 127 ± 33.6 (8)B | |
| EC50 | 990 ± 387 (8)A | 425 ± 101 (6) | 268 ± 66.6 (6) | 509 ± 134 (8)B | ||
| EC80 | 4329 ± 1767 (8) | 1463 ± 466 (6) | 1133 ± 277 (6) | 2851 ± 1046 (8)C | ||
| SNP | EC20 | 130 ± 45.4 (10) | 88.9 ± 20.2 (6) | 136 ± 36.8 (7) | 179 ± 64.5 (7)D | |
| EC50 | 521 ± 181 (10) | 356 ± 80.7 (6) | 544 ± 147 (7) | 715 ± 258 (7)D | ||
| EC80 | 2748 ± 1422 (10) | 1955 ± 651 (6) | 3272 ± 122 (7) | 4781 ± 2216 (7)E |
All data are expressed as means ± SE with number of fetuses in parenthesis. All data for wild-type (WT)/P0 fetuses in control and sildenafil citrate (SC)-treated mice are expressed as effective concentration (EC in nM).
Reduced ACH sensitivity in SC-treated WT male vs. control WT male (EC20, EC50; P < 0.05; Mann-Whitney U-test). B Reduced ACH sensitivity in SC-treated P0 female vs. control P0 female (EC20, EC50; P < 0.01, Mann-Whitney U-test). CReduced ACh sensitivity in SC-treated P0 female vs. control P0 female (EC80; P < 0.001, Mann-Whitney U-test). DReduced sodium nitroprusside (SNP) sensitivity in SC-treated P0 female vs. control P0 female (EC20, EC50; P < 0.01). EReduced SNP sensitivity in SC-treated P0 female vs. control P0 female (EC80; P < 0.05, Mann-Whitney U-test).